Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The most commonly reported adverse events in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, and diarrhoea consistent with the GLP-1 receptor agonist class
The psychological impact of persistent pain should not be underestimated, and addressing the cognitive and emotional components of the pain experience can meaningfully improve outcomes
Address Your Concerns
Rapid weight loss associated with semaglutide therapy may lead to reduced intake of nutrients, including iron, vitamin B12, or folate, which are recognized risk factors for secondary RLS
US$ 27.64
US$ 28.95
US$ 20.96
US$ 20.77
US$ 27.60
